| ￥2300 | |
| Z05509-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity |
> 95% as determined by BisTris PAGE > 90% as determined by HPLC |
|
| Endotoxin Level | Less than 0.05EU per μg by the LAL method. | |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-6, Human at 2μg/ml (100μl/Well) on the plate can bind Human IL6 R alpha, hFc Tag. Test result was comparable to standard batch. Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.1 0.5 ng/mL. Test result was comparable to standard batch. |
|
| Expression System | E.coli | |
| Theoretical Molecular Weight | 20.8 kDa | |
| Apparent Molecular Weight | The protein has a predicted 20.8 kDa same as Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | IL-6 (Interleukin-6) is a pleiotropic cytokine that acts in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression.Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. |
| Synonyms | IFN-beta-2; IL6; IL-6; BSF-2; CDF; MGI-2A; Interleukin-6; HSF; IFNB2; HGF;IFN-β-2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
